Please assess the completion status of the following clinical trial:

Trial Title: Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed solid tumor (leukemia and lymphoma are excluded)~2. Malignancy that is incurable and for which standard (FDA approved or established standard clinical practice) curative, or palliative measures do not exist or are no longer effective~3. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.~4. Minimum expected life expectancy \> 6 months~5. One or more measurable lesion(s) (target lesion\[s\]) that can be accurately measured in at least 1 dimension~6. Willing to adhere to the prohibitions and restrictions specified in the protocol~7. The patient must sign an informed consent form (ICF)~Exclusion Criteria:~1. Recent major surgery (within the past 14 days)~2. Chemotherapy or dose of other potentially myelosuppressive treatment within 3 weeks prior to Screening (6 weeks for nitrosoureas or mitomycin C)~3. No more than a total cumulative dose of 450 mg/m\^2 of prior doxorubicin chemotherapy~4. Definitive radiotherapy (\> 10 fractions and maximal area of hematopoietic active Bone Marrow treated greater than 25%) within 4 weeks prior to Screening~5. Palliative radiotherapy (≤ 10 fractions) within 2 weeks prior to Screening~6. Known brain metastases, except brain metastases that have been previously removed or irradiated and currently have no clinical impact~7. Residual adverse events due to previously administered agents (except alopecia, stable residual neuropathy, and residual hand, foot syndrome) that have not recovered to Grade 1 or below in severity level (based on NCI CTCAE) before Screening~8. Ascites requiring active medical management, including paracentesis~9. Pleural effusion requiring active medical management~10. Peripheral bilateral edema requiring active medical management~11. Hyponatremia (serum sodium value less than 130 mEq/L)~12. History of allergic reactions attributed to compounds of similar chemical or biologic composition to briciclib~13. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, bleeding, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements~14. History of myocardial infarction~15. Any other concurrent investigational agent or chemotherapy, radiotherapy, hormonotherapy, or immunotherapy. Exceptions are long-term hormonals for prostate (eg, goserelin) and octreotide for neuroendocrine malignancies~16. Patients who are positive for human immunodeficiency virus type 1 (HIV-1) and are receiving combination anti-retroviral therapy~17. Hemoglobin (Hgb) \< 9 g/dL~18. White Blood Cell count (WBC) \< 4,000/µL~19. Absolute Neutrophil Count (ANC) \< 1,500/µL~20. Platelet (PLT) count ≤ 100,000/µL~21. Total bilirubin greater than 1.5 x the institutional upper limit of normal (ULN)~22. Aspartate transaminase (AST) or alanine transaminase (ALT) ≥ 2.5 x institutional ULN. If liver function abnormalities are due to metastatic disease, patients are eligible provided the ALT and AST are \< 5 x ULN~23. Serum creatinine \> 2 x ULN

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- briciclib (Type: EXPERIMENTAL): The starting dose of briciclib in the Escalation Stage will be 17 mg/week, with subsequent dose escalation levels of 35 mg, 70 mg, 140 mg, 280 mg, 560 mg, and 1120 mg. The dose of briciclib in the RPTD Confirmation Stage will be the dose as determined during the escalation stage. At each dose level, briciclib will be administered as a 2-hour intravenous infusion, once-a-week per 3-week cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).